Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medimmune Bets on Pain: Why The Large Molecule Specialist Thinks It Can Win

Executive Summary

AstraZeneca PLC has operated Medimmune as an independent R&D subsidiary since 2007, with Centers of Excellence organized around large molecules in targeted therapeutic areas. The company retains small molecule development under the AZ umbrella, leading to what some might refer to as friendly" co-opetition."

You may also be interested in...



Biologics Swing For The Fences: Payer Perspectives On Antibodies In Primary Care

Companies with large-molecule expertise increasingly are eyeing primary care markets, confident that improvements in safety and efficacy will make them competitive with oral standards of care.

J&J Wins Nucynta ER Approval, Targets Chronic Pain Market

The company plans a push for the extended release formulation of its opioid medication.

AstraZeneca Rebuilds Its R&D, With Payers In Mind

When Martin Mackay joined AstraZeneca PLC as president, global research & development, from Pfizer Inc. one year ago, one of his objectives was to "put AstraZeneca's R&D back on the map."

Related Content

Topics

UsernamePublicRestriction

Register

PS053536

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel